{"cluster": 63, "subcluster": 8, "abstract_summ": "In contrast, PK predictions of chloroquine in the lungs using in-vivo data or human physiologically-based PK models, suggest that doses as low as 3mg/kg/day for 3 days could deliver exposures that are significantly higher than reported antiviral-EC90s for up to a week.Results: Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC50, even for a dose level 10x higher than the approved dose.Plasma total Cmax was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung Cmax after administration of each single dose.A PBPK model of CQ was successfully developed to optimize dosage regimens for patients with COVID-19.We use a mechanistic lung model to demonstrate that accumulation of chloroquine (CQ), hydroxychloroquine (HCQ) and azithromycin (AZ) in the lungs is sensitive to changes in lung pH, a parameter that can be affected in patients with COVID\u201019.Even with higher exposure in lungs than plasma, ivermectin is unlikely to reach the IC50 in lungs after single oral administration of the approved dose (predicted lung: 0.0857 uM) or at doses 10x higher that the approved dose administered orally (predicted lung: 0.817 uM).", "title_summ": "The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose SelectionPredictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin with Different Dosing Regimens used in COVID\u201019 Clinical TrialsRemdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional BenefitModel based approach for estimating the dosage regimen of indomethacin a potential antiviral treatment of patients infected with SARS CoV-2Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic modelImpact of disease on plasma and lung exposure of chloroquine, hydroxy\u2010chloroquine and azithromycin: application of PBPK modellingThe Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID\u201019Population pharmacokinetics and pharmacodynamics of chloroquine in a Plasmodium vivax volunteer infection studyConcerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infectionChloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety PropertiesSafety, Tolerability, and Pharmacokinetics of Remdesivir, an Antiviral for Treatment of COVID-19, in Healthy Subjects.", "title_abstract_phrases": "In contrast, PK predictions of chloroquine in the lungs using in-vivo data or human physiologically-based PK models, suggest that doses as low as 3mg/kg/day for 3 days could deliver exposures that are significantly higher than reported antiviral-EC90s for up to a week.Results: Plasma ivermectin concentrations of total (bound and unbound) and unbound concentrations do not reach the IC50, even for a dose level 10x higher than the approved dose.Plasma total Cmax was determined and then multiplied by the lung:plasma ratio reported in cattle to predict the lung Cmax after administration of each single dose.A PBPK model of CQ was successfully developed to optimize dosage regimens for patients with COVID-19.Impact of disease on plasma and lung exposure of chloroquine, hydroxy\u2010chloroquine and azithromycin: application of PBPK modellingWe use a mechanistic lung model to demonstrate that accumulation of chloroquine (CQ), hydroxychloroquine (HCQ) and azithromycin (AZ) in the lungs is sensitive to changes in lung pH, a parameter that can be affected in patients with COVID\u201019.Even with higher exposure in lungs than plasma, ivermectin is unlikely to reach the IC50 in lungs after single oral administration of the approved dose (predicted lung: 0.0857 uM) or at doses 10x higher that the approved dose administered orally (predicted lung: 0.817 uM)."}